The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36826422.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0048 and PMC identifier 10159911.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698.
Medical subject headings
- Ovarian Neoplasms